Growth Parameters of Turkish Children With an Autoinflammatory Disease Before and After Canakinumab Treatment

Balci S., KIŞLA EKİNCİ R. M., Dogruel D., ALTINTAŞ D. U., YILMAZ M.

INDIAN PEDIATRICS, cilt.57, sa.7, ss.637-640, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 7
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1007/s13312-020-1892-9
  • Dergi Adı: INDIAN PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.637-640
  • Çukurova Üniversitesi Adresli: Evet

Özet

Objective To evaluate the effect of canakinumab on growth parameters of patients with autoinflammatory diseases. Methods This retrospective study included Colchicine resistant familial Mediterranean fever (FMF), Mevalonate kinase deficiency (MKD), Tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), Deficiency of adenosine deaminase 2 (DADA2) patients treated with canakinumab for at least six consecutive months. Results Eleven patients with FMF, 9 with MKD, 3 with TRAPS, and 1 with DADA2 were included. The median age (range) at diagnosis and drug initiation was 6.06 (1.45-16.06) years and 9.72 (1.82-19.11) years, respectively. The mean weight, height, and BMI SD scores significantly increased after canakinumab. There were significant improvements in laboratory parameters and disease activities. However, growth parameters after the drug did not differ according to gender, the duration of diagnostic delay, and age at the diagnosis. Conclusion Canakinumab seems to have a positive effect on growth in patients with autoinflammatory diseases by controlling disease activity and inflammation.